FDA Strengthens Warnings on Sleep Drugs
Posted on: Friday, 16 March 2007, 12:00 CDT
The FDA has requested stronger labeling for sedative-hypnotic drug products, a class of sleep disorder drugs, to include risks such as severe allergic reactions and sleep driving.
Sleep driving is defined as driving while not fully awake after ingestion of a sedative-hypnotic product, with no memory of the event. Along with the labeling revisions, the FDA has requested that each product manufacturer send letters to health care providers to notify them about the new warnings. The medications include Sanofi-Aventis' Ambien and Abbott's Placidyl.
"There are a number of prescription sleep aids available that are well-tolerated and effective for many people," said Steven Galson, director of FDA's Center for Drug Evaluation and Research. "However, after reviewing the available post-marketing adverse event information for these products, FDA concluded that labeling changes are necessary to inform health care providers and consumers about risks."
Anaphylaxis (severe allergic reaction) and angioedema (severe facial swelling), which can occur as early as the first time the product is taken. Complex sleep-related behaviors which may include sleep-driving, making phone calls, and preparing and eating food while still asleep.
Source: Datamonitor
Related Articles
- CBI Announces the Agenda for its Forum on FDA's Structured Product Labeling (SPL R4)
- Cumberland Pharmaceuticals Reports FDA Approval for Updated Labeling of Acetadote(R)
- FDA OKs Raptiva Drug Labeling Changes
- Merck Receives FDA Approval for Expanded Labeling of Januvia
- Genzyme Receives FDA Approval for New Labeling for Carticel(R)
- Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
- Datascope Receives FDA Clearance to Include Depth-of-Anesthesia Monitoring in the Spectrum(R) OR Monitor
- Research and Markets: In 2005, Huntleigh Healthcare Launched Several New Products, Including the Enterprise Modular Hospital Bed and the Flowtron Hydroven IPC Therapy Range
- United Therapeutics Announces FDA Approval of Expanded Label Indication and Satisfaction of Subpart H Accelerated Approval Commitment
- OraSure Technologies to Present Before the FDA Blood Products Advisory Committee on November 3, 2005
 |
 |
User Comments (0)
RSS Feeds